Alcohol and drug dependence are serious public health problems worldwide. The prevalence of alcohol and drug dependence in the United States and other parts of the world is significant. Given the limitations in the efficacy of current pharmacotherapies to treat these disorders, research in developing alternative pharmacotherapies continues. Preclinical and clinical evidence thus far has indicated that brain nicotinic acetylcholine receptors (nAChRs) are important pharmacological targets for the development of medications to treat alcohol and drug dependence. The nAChRs are a super family of ligand gated ion channels, and are expressed throughout the brain with twelve neuronal nAChR subunits (α2–α10 and β2–β4) identified. Here, we review preclinical and clinical evidence involving a number of nAChR ligands that target different nAChR subtypes in alcohol and nicotine addiction. The important ligands include cytisine, lobeline, mecamylamine, varenicline, sazetidine A and others that target α4β2* nAChR subtypes as small molecule modulators of the brain nicotinic cholinergic system are also discussed. Taken together, both preclinical and clinical data exist that support nAChR–based ligands as promising therapeutic agents for the treatment of alcohol and drug dependence.

Keywords: nicotinic receptor, alcohol dependence, nicotine addiction, drug addiction, CNS disorders, drug development, animal models
domain regulate ion conductance through the pore. The brain nAChR subunits are classified as alpha (α2–α10) or beta (β2–β4), according to the protein sequence and presence in the N-terminal domain of the α-subunits of two adjacent cysteines at positions 192 and 193, which are thought to participate in the ligand binding site. While the residues in the α-subunit form the primary face of the agonist binding site and determine the affinity for the ligand, the β-subunit forms the complementary face of the binding site and contributes to ligand selectivity (Gotti et al., 2009). Heteromeric receptors are assembled from both alpha (α2–α6) and beta subunits, while homomeric receptors are formed by alpha subunits only. Thus, heteromeric nAChRs contain two ligand binding sites (at the interface of α and β subunits), whereas homomeric nAChRs contain five ligand binding sites.

The nAChRs with identical subunit composition may differ in the stoichiometry of subunits, thus contributing to the variable channel kinetics, agonist binding, and pharmacological heterogeneity of nAChRs (Champtiaux et al., 2003; Moroni and Bermudez, 2006; Millar and Gotti, 2009). For example, (α4)(3)/(β3)1 nAChR subtypes are more sensitive (show higher affinity) to agonists in comparison to low affinity (α4)(3)/(β3)2 subtypes, indicating that changes in nAChR stoichiometry can elicit different physiological and pharmacological responses (Nelson et al., 2003). More than 90% of the receptor subtypes in the rodent brain are α4β2 nAChRs (Flores et al., 1992; Gotti et al., 2007; Albuquerque et al., 2009). However, the β2 subunit is less ubiquitous in the human brain (Paterson and Nordberg, 2000). The α4β2 nAChRs are widely distributed in various neuroanatomical regions, including the mesocorticolimbic dopamine system (Perry et al., 2002; Zoli et al., 2002; Gotti et al., 2007, 2009, see Table 1). The α7 nAChRs are also highly expressed in the brain and predominantly located in the hippocampus, cortex, and subcortical limbic regions (Gotti et al., 2007, 2009, see Table 1). Previous studies suggest that nAChRs are expressed at the synapse, cell body, and axons (Livingstone and Wonnacott, 2009). Presynaptic nAChRs are involved in regulating the release of ACh (Wilkie et al., 1993), NE (Clarke and Reuben, 1996), dopamine (Grady et al., 1992), glutamate (Alkondon et al., 1997), and GABA (Yang et al., 1996). Evidence indicates that dopamine release is modulated by α4β2*, α3β2*, and α6* nAChRs (*indicates possible involvement of other receptor subunits) in nigrostriatal terminals (Le Novere et al., 1996; Luo et al., 1998; Wonnacott et al., 2000; Salminen et al., 2004). Glutamate release is regulated by presynaptic α7 nAChRs (Mansvelder et al., 2002). Similar to other ligand-gated ion channels, nAChRs modulate the flow of ions across the cell membrane under the influence of an extracellular signaling molecule. A net influx of cations (Na+, Ca++) through the ion channel depolarizes the cell membrane and increases neuronal excitability. The Ca++ entry through some nAChRs exerts additional effects on intracellular signaling cascades. ACh, the endogenous ligand of nAChRs, is released from the presynaptic cholinergic axon terminals and binds to the extracellular ligand binding domain of the receptor. Binding of ACh or exogenous ligands to the orthosteric site influences transition rates between three distinct functional states of nAChRs: the resting, open, and desensitized states. The rate constants between the functional states are dependent on the specific combination of subunits and the chemical characteristics of the ligand that is bound. Prolonged exposure to small doses of nicotine rapidly activates nAChRs initially, which is followed by desensitization of various nAChR subtypes (Quick and Lester, 2002). Heteromeric subtypes such as α4β2* or α6β2* slowly desensitize in an activity-dependent manner when exposed to low concentrations of nicotine, whereas homomeric subtypes such as α7* nAChRs are much less susceptible to desensitization (Woollorton et al., 2003) to low concentration of nicotine. The nAChR subtypes are stimulated or blocked by a number of agonists or antagonists (Gotti et al., 2007, 2009, see Table 1). Furthermore, brain nAChRs can be desensitized by continuous or repeated exposure to an agonist (e.g., nicotine) that results in progressive decreases in response to the drug. However, antagonism produced by specific ligand binding to the nAChR is somewhat different pharmacologically from these desensitized states (Buccafusco et al., 2009).

Recent work with nAChR subtype knockout (KO) mice have provided important information on both brain nAChR function and their mediation of addiction related behavior (Fowler et al., 2008; Mineur and Picciotto, 2008; Changeux, 2010). For example, early research showed that mice lacking the β2 subunit do not display several nicotine-associated responses, including nicotine-induced DA release in the dorsal and ventral striatum as well as, nicotine-elicited increases in the firing rate of associated DA neurons (Picciotto et al., 1995, 1998). The lack of nicotine's effect on the mesolimbic DA systems in β2 subtype nAChR KO mice is consistent with the absence of nicotine self-administration by these animals (Picciotto et al., 1998). The α4 subunit requires the β2 subunit for assembly in the majority of heteromeric nAChRs in the brain, these and other studies using genetically modified mice suggest that α4β2* nAChRs are critical for nicotine-related reward behaviors (Ross et al., 2000; Tapper et al., 2004). Despite the distribution of the α7 subunit in the brain, in particular its presence in the mesocorticolimbic
system, studies in α7 KO mice are not definitive about a role for the α7 subunit in nicotine reward and conditioning (Mineur and Picciotto, 2008). However, α7 nAChRs are important for long-term potentiation, neuroplasticity associated with learning and memory, in the mesolimbic reward pathway (Mineur and Picciotto, 2008). KO mouse studies targeting the α6 subunit indicate that α6 partners with β2 nAChRs and may play an important role in nicotine addiction related behavior (Champtiaux et al., 2002). Recently, studies with transgenic over expression of the α5, α3, and β4 receptor subunit genes indicate these subunits have a potential, but complex, role in the modulation of nicotine related behaviors (Gallego et al., 2012).

Similar to research on the involvement of AChR subunits in nicotine-induced behaviors, a number of genetic studies have been conducted to identify the role of nAChR subtypes in alcohol drinking behavior. For example, acute alcohol drinking behavior is reduced in α4 KO mice compared to wild type (WT) indicating a role for the nAChR α4 subunit in alcohol abuse (Hendrickson et al., 2010, 2013). Similarly, alcohol-related behaviors and alcohol-induced midbrain dopaminergic function is decreased in α4 KO mice (Liu et al., 2013). On the other hand, β2 KO mice behave similarly to WT type mice in alcohol drinking behaviors (Kamens et al., 2010). In addition, α6 KO and β3 KO mice also display alcohol drinking behavior that is similar to WT mice in a two-bottle alcohol drinking paradigm (Kamens et al., 2010). Moreover, α7 KO and WT mice consume similar amounts of alcohol, although there was a potential gender effect regarding α7 nAChR effects on ethanol consumption (Kamens et al., 2010). And, again, α5 KO mice do not differ in acute ethanol consumption compared to WT mice (Santos et al., 2012). Like nicotine-related behavior (see above), studies with transgenic over expression of the α5, α3, and β4 receptor subunit genes indicate these subunits have a complex role in the modulation of alcohol related behaviors (Gallego et al., 2012). Together, these data indicate that nAChRs containing α5, α6, β2, or β3 subunits may not be critical in alcohol drinking behaviors. Overall, the evidence indicates that α4 receptors in the midbrain may be associated with alcohol related behavior. Taken together, brain nAChRs represent a diverse class of receptor subtypes which are involved in a number of neurobiological functions and are associated with neurological and psychiatric disorders, including nicotine and alcohol dependence.

**NICOTINIC RECEPTORS: TARGETS TO TREAT ALCOHOL DEPENDENCE**

As with the treatment of alcohol dependence, the existing FDA-approved medications for nicotine dependence such as bupropion and varenicline, have had limited efficacy with continued significant relapse rates (Volkow and Skolnick, 2012). These brain targets will open new avenues for better treatment strategies targeting alcohol or drug dependence by interrupting the dependence and relapse cycle. Research indicates that brain nAChR subtypes are important mediators of the rewarding effects of alcohol (ethanol) and drugs of abuse (Blomqvist et al., 1993; Ericson et al., 1998; Lé et al., 2000; Soderpalm et al., 2000; Chi and de Wit, 2003; Young et al., 2005; Reus et al., 2007; Steensland et al., 2007; Bell et al., 2009; Liu et al., 2013). It is widely known that systemic or local administration of mecamylamine, a non-selective nAChR antagonist reduces ethanol drinking in a number of animal models (Ericson et al., 1998; Lé et al., 2000; Soderpalm et al., 2000; Steensland et al., 2007). Also, it has been proposed that nAChRs in the VTA regulate ethanol consumption and associated mesocorticolimbic neurochemical effects (e.g., dopamine release) in various animal models (Ericson et al., 1998; Chi and de Wit, 2003). However, mecamylamine either reduces or fails to decrease ethanol drinking behavior in humans (Blomqvist et al., 1996, 2002; Young et al., 2005), indicating mixed efficacy for treating ethanol dependence through nAChR blockade. Understandably, these mixed results have limited mecamylamine's clinical utility for ethanol drinking cessation. On the other hand, a selective α4β2 antagonist, dihydro-β-erythroidine failed to suppress ethanol consumption, thus suggesting a role for α6β2* but not the α4β2* subtypes in alcohol reinforcement (Larsson et al., 2002; Larsson and Engel, 2004). Similarly, the α7 nAChR antagonist methyllycaconitine was ineffective in reducing ethanol intake in an animal model of excessive ethanol drinking (Kamens et al., 2010). Varenicline, a partial α4β2* nAChR agonist and FDA-approved medication for smoking cessation (Reus et al., 2007), was found to reduce alcohol drinking in both animal models and humans (Steensland et al., 2007; McKee et al., 2009, 2013; Hendrickson et al., 2010; Kamens et al., 2010; Bito-Onon et al., 2011; Chatterjee et al., 2011; Sajja and Rahman, 2011, 2013a; Mitchell et al., 2012; Litten et al., 2013; Sotomayor-Zarate et al., 2013; Kaminski and Weerts, 2014). The drug was developed as a potent high-affinity partial agonist at α4β2* nAChRs (Reus et al., 2007), but also targets other nAChR subtypes as well. Therefore, the role of specific nAChR subtypes needs further investigation.

Additional nAChR ligands such as cytisine, a partial agonist at α4β2* and lobeline, a non-selective antagonist were found to reduce alcohol consumption and nicotine-induced alcohol drinking (Bell et al., 2009; Hendrickson et al., 2009; Chatterjee et al., 2011; Sajja and Rahman, 2011, 2012, 2013a).

These nAChR ligands also altered alcohol-induced increases in mesolimbic tissue DA levels (Sajja et al., 2010) in mice, confirming the important role of nAChRs in alcohol drinking and suggesting their involvement in alcohol dependence. Moreover, cytisine and lobeline were found to decrease alcohol self-administration in high alcohol drinking rats (Bell et al., 2009), a genetic animal model for alcohol abuse and dependence (Bell et al., 2012), and mice (Sajja and Rahman, 2011), suggesting that lobeline and cytisine are strong candidates for treating alcohol dependence. Sazetidine-A, a novel compound that selectively desensitizes α4β2 nAChRs, with partial agonistic activity (Xiao et al., 2006; Rezvani et al., 2013), was shown to reduce alcohol drinking in alcohol-preferring rats (Xiao et al., 2006; Rezvani et al., 2010). The evidence suggests that the desensitizing effects of sazetidine on α4β2 nAChR subtypes may account for these reductions in alcohol self-administration. Overall, sazetidine-A may have potential for the management of alcohol dependence by targeting brain nAChR-associated mechanisms.

The existing animal and human studies suggest that alcohol-induced activation of the mesolimbic DA system involves brain nAChR stimulation. The rewarding effects of alcohol are dependent on the activation of the nAChRs in the mesolimbic...
DA system (Rollemma et al., 2007). Overall, it is clear that brain nAChRs have emerged as critical targets for the reinforcing actions and DA activating effects of alcohol. Thus, ligands or compounds targeting nAChRs, other than those selective for α4β2 nAChRs, have potential for treating alcohol dependence in humans. For example, CP-601932 and PF-4575180, partial agonists at α3β4+ nAChR were found to reduce alcohol consumption and preference in rats, confirming a role for additional nAChR subtypes in alcohol dependence (Chatterjee et al., 2011). Overall, nAChR partial agonists, antagonists or other ligands (see Table 2) target several nAChRs, such as α4β2* and/or α3β4+ in order to modulate alcohol self-administration, underscoring the need to conduct more subunit-specific nAChR research regarding alcohol abuse and dependence. While nAChR ligands or partial agonists show great promise in reducing alcohol self-administration, evidence indicates that these ligands also decrease the alcohol deprivation effect, a validated animal model of relapse behavior (McKinzie et al., 1998; Spanagel and Hölter, 1999; Rodd et al., 2004; Melendez et al., 2006; Sparta et al., 2009; Bell et al., 2012). Emerging preclinical studies suggest that nicotine exposure re-instates alcohol seeking behaviors in rodents following extinction of alcohol reinforcement (Lê et al., 2003; Hauser et al., 2012). Furthermore, nAChRs were found to regulate deprivation-induced re-exposure of alcohol seeking in long-term alcohol exposed animals (Kuzmin et al., 2009; Rezvani et al., 2010). The nAChR partial agonist varenicline or cytisine that targets α4β2* were found to reduce cue-induced alcohol relapse (Wouda et al., 2011) and the ADE (Sajja and Rahman, 2013a) in animal models. Thus, neurobiological mechanisms associated with relapse are important for new drug developments for alcohol abuse and dependence (McBride et al., 2002; Weiss and Porrino, 2002; Koob and Volkow, 2010).

**NICOTINIC RECEPTORS: TARGETS TO TREAT NICOTINE OR OTHER DRUG DEPENDENCE**

Evidence utilizing a wide variety of pharmacological and molecular approaches indicates the important role of nAChRs in modulating nicotine self-administration and associated neurochemical effects (Corrigall et al., 1992; Tuesta et al., 2011). As with alcohol abuse and its treatment, nicotinic ligands that target α4β2* subtypes, particularly those expressed in the mesolimbic DA system, show promise for the management of nicotine addiction (Damaj et al., 1997; Coe et al., 2005; Rollemma et al., 2007, 2010; Benowitz, 2009). Several therapeutic drug candidates which are either partial agonists or antagonists at nAChRs have been investigated for nicotine taking behavior in preclinical and clinical studies. Varenicline, an FDA approved medication for smoking cessation and an analog of cytisine, shows promise re-instates alcohol seeking behaviors in rodents following extinction of alcohol reinforcement (Lê et al., 2003; Hauser et al., 2012).

### Table 2 | Brain nAChR subtypes and pharmacological agents involved in alcohol/nicotine or substance use disorder.

| nAChR subtype/addiction disorder | nAChR ligand | Primary mode of action |
|---------------------------------|-------------|-----------------------|
| α4β2* AUD or NUDa               | Cytisine    | Partial agonist       |
| α4β2* AUD, NUD, or SUDb         | Varenicline | Partial agonist       |
| α4β2* AUD, or NUDc              | Szazetidine A | Desensitization/partial agonist |
| α3β4* AUDd                      | CP-601932   | Partial agonist       |
| α3β4* AUDe                      | PF-4575180  | Partial agonist       |
| α4β2* or other β2 containing subtypes AUD, NUD, or SUDf | Mecamylamine | Antagonist |
| α4β2* or other β2 containing subtypes AUD or SUDg | Lobeline | Antagonist |
| α3β4* NUDh                      | AT-1001     | Antagonist            |
| α4β2* NUDi                      | 2-fluro-3-(4-nitrophenyl) deschloroepibatidine | Antagonist |
| α3β2* NUDj                      | α-conotoxin MII | Antagonist |

*Indicates other α or β subunits such as α3, α5, or α6 and β3 or β4.
AUD, Alcohol use disorder; NUD, Nicotine use disorder; SUD, Substance use disorder.

Bell et al., 2009; Hendrickson et al., 2009; Chatterjee et al., 2011; Sajja and Rahman, 2011, 2012, 2013a.
Steensland et al., 2007; McKee et al., 2009; Guillem and Peoples, 2010; Hendrickson et al., 2010; Kamens et al., 2010; Bito-Onon et al., 2011; Chatterjee et al., 2011; Wouda et al., 2011; Mitchell et al., 2012; Plebani et al., 2012; Volkow and Skolnick, 2012; Liu et al., 2013; Litten et al., 2013; McKee et al., 2013; Sajja and Rahman, 2013a; Sotomayor-Zarate et al., 2013; Kaminski and Weerts, 2014.
Xiao et al., 2006; Levin et al., 2010; Rezvani et al., 2010.
Chatterjee et al., 2011.
Ericson et al., 1998, 2009; Lê et al., 2000; Soderpalm et al., 2000; Blomqvist et al., 2002; Young et al., 2005; Liu et al., 2007; Steensland et al., 2007.
Bell et al., 2009; Hendrickson et al., 2009; Chatterjee et al., 2011; Sajja and Rahman, 2011, 2012, 2013a,b; Roni and Rahman, 2014.
Toll et al., 2012.
Tobey et al., 2012.
Crooks et al., 2014.

Rezvani et al., 2010). Bupropion, an FDA approved smoking cessation agent was believed to target α3β2 and/or α4β2 nAChR subtypes in addition to its primary inhibitory mechanisms on the dopamine and norepinephrine transporters (see Crooks et al., 2014). Mecamylamine, a non-selective antagonist at nAChRs, has been investigated and appears to have some efficacy for smoking cessation in a number of clinical studies (Lundahl et al., 2000; Schnoll and Lerman, 2006). Mecamylamine was also reported to decrease cue-induced reinstatement of nicotine-taking behavior (Liu et al., 2007) likely by targeting β2-containing nAChR.
subtypes. Nevertheless, the clinical efficacy of mecamylamine is tempered by its peripheral side effects (Rose, 2009). Recently, lobeline, a non-selective antagonist at nACHRs, was found to reduce nicotine withdrawal-induced depression-like behavior; again, likely by targeting β2-containing brain nACHRs (Ronid and Rahman, 2014). Thus, lobeline may also have potential in preventing smoking relapse by counteracting nicotine withdrawal-induced depression in humans. Similarly, emerging preclinical studies suggest that selective antagonists at α-µ-conotoxin MII (α-ÇtxMII) sensitive nACHRs subtypes have great promise in reducing nicotine self-administration (Crooks et al., 2014).

Early work showed that the novel nACHR antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide reduced nicotine self-administration and nicotine-induced DA function and release in reward-relevant brain regions in preclinical models (Neugebauer et al., 2006; Rahman et al., 2007; Dwoskin et al., 2009), suggesting a possible drug candidate for treating nicotine addiction. Recently, 2-fluro-3-(4-nitrophenyl) deschloropipi- dine, a potent α4β2 nACHR antagonist was found to decrease nicotine self-administration in rats (Tobey et al., 2012). In addition, AT-1001, a high-affinity and selective antagonist at α3β4 nACHRs reduced nicotine self-administration in rats (Toll et al., 2012), suggesting an important role for this α3β4 subtype in nicotine addiction. Taken together, these data indicate that nACHRs, specifically, α4β2, α3β2 are important therapeutic targets for all three phases of nicotine addiction, including acquisition and maintenance of nicotine-taking behavior, withdrawal symptoms associated with cessation of nicotine-intake and vulnerability to relapse behavior. Thus, emerging partial agonists and/or antagonists (see Table 2) at nACHRs have therapeutic potential that needs to be further investigated and developed for clinical management of nicotine addiction.

Additional drugs such as galantamine, an acetylcholinesterase (AChE) inhibitor and positive allosteric modulator of α7 and α4β2 nACHRs (Harvey, 1995) has been shown to reduce both nicotine self-administration and reinstatement of nicotine-seeking behavior in animal models (Hopkins et al., 2012). Similarly, rivastigmine, another AChE inhibitor attenuates tobacco craving and smoking in alcohol- and methamphetamine-dependent smokers (Diehl et al., 2009; De La Garza and Yoon, 2011) and desire to use methamphetamine in the latter (De La Garza et al., 2012). Recently, varenicline was found to reduce the positive subjective effects of methamphetamine in human volunteers suggesting a treatment option for methamphetamine dependence (Verrico et al., 2014). This highlights the important role of the nACHR system in poly-drug abuse and dependence. Taken together, these preclinical and clinical studies suggest that AChE inhibitors likely affect nicotine taking behavior by targeting nACHRs and ACh levels along with their modulation of other neurotransmitter systems (Hopkins et al., 2012).

With regard to other psychostimulants, a number of nACR antagonists were found to decrease cocaine self-administration, prevent cue-induced craving for cocaine, and to decrease cocaine effects in a place preference paradigm or reduce cocaine-induced behavioral sensitization (Levin et al., 2000; Zachariou et al., 2001; Champtiaux et al., 2006; Hansen and Mark, 2007) suggesting a direct involvement of nACHRs in cocaine-taking and -seeking behavior. In addition, recent studies indicate that varenicline reduces cocaine-induced reward in rodents and humans (Guillen and Peoples, 2010; Plebani et al., 2012). In contrast, varenicline was found ineffective in reducing cocaine self-administration in a primate model (Gould et al., 2011), indicating mixed effects across models which may be due to species’ differences. Consistent with behavioral studies, systemic application of nACHR antagonists significantly reduces cocaine-induced increases in mesolimbic DA-release (Zanetti et al., 2006). Thus, again, both behavioral and neurochemical evidence support an important role for nACHRs in cocaine-taking and -seeking behavior. Similar to its effects on cocaine, nACHRs appear to mediate cannabinoid addiction as well. For example, methyllycaconitine, a α7 nACHR antagonist was found to reduce 9-tetrahydrocannabinol or cannabinoid-1 receptor agonist-induced behavioral and neurochemical effects in animal models, suggesting a critical role in regulating the rewarding effects of cannabinoids (Solinas et al., 2007). Similarly, other animal studies suggest that nACHRs are also important therapeutic targets for treating opiate addiction (Glick et al., 2002; Biala and Staniak, 2010; Hart et al., 2010; Feng et al., 2011). Overall, emerging data indicates that nACHRs are important targets for psychostimulant abuse and addiction, which will probably involve targeting specific nACHR subtypes and their neuromodulatory mechanisms.

**NICOTINIC RECEPTOR GENE VARIATIONS AND ADDICTION**

Finally, given the increasingly recognized role of pharmacogenetics/pharmacogenomics in the treatment of addiction (e.g., King et al., 2012; Uhl et al., 2014), it is important to provide a general statement on some of the polymorphisms with a significant association to the initiation, maintenance, relapse, craving and/or treatment outcomes related to addiction. Given the primary addictive component of ingested tobacco is nicotine, it stands to reason that by far the addictive behavior most commonly examined, regarding its association with the nACHR, is nicotine/tobacco addiction. In Indian subjects, variations in the CHRNA5 risk polymorphism (rs16969968) are associated with increased probability of nicotine dependence (Anantharaman et al., 2014). The CHRNA5 risk polymorphism (rs16969968) also has a significant association with nicotine addiction strength (level of physical addiction) with different allelic expression conferring either increased or decreased levels of nicotine dependence (Wojas-Krawczyk et al., 2012). In addition, the CHRNA5 risk polymorphism (rs16969968) is associated with significant increases in fMRI activity of women shown smoking images (Janes et al., 2012). Similarly, in female Canadian citizens of Ontario, the presence of the CHRNA5 risk polymorphism (rs16969968) is significantly increased in smokers women compared to non-smokers women and individuals with low nicotine dependence (Wassenaar et al., 2011). The CHRNA3 risk polymorphism (rs1051730) has been shown to have a significant association with level of nicotine in two heavy smoking regional Italian
populations (Sorice et al., 2011). The CHRNA3 risk polymorphism (rs1051730) also has a significant association with short-term (4 week) nicotine abstinence-rates in treatment-seeking smokers (Munafó et al., 2011); although, another study did not find a significant association between this polymorphism and willingness to quit smoking (Marques-Vidal et al., 2011). Two other polymorphisms that have significant predictive value for smoking cessation following treatment with a transdermal nicotine patch and/or bupropion are the CHRNA5 (rs680244) and CHRNA4 (rs12914008) polymorphisms (Sarginson et al., 2011). In an early Finnish study, it was found that variations in the CHRN-G-CHRND gene cluster on chromosome 2 were significantly associated with cotinine levels but not number of cigarettes smoked per day suggesting a possible gene-gene interaction with nicotine metabolizing genes (Keskitalo-Vuokko et al., 2011).

Variants in the CHRNA2 and CHRNA6 on chromosome 8 are also associated with increased risk for nicotine dependence in Americans, with the latter being significant in both those of European and African descent and the former being significant in only those of African descent (Wang et al., 2014). A previous study found that the CHRNA3 risk polymorphism (rs1451240) significantly increased the probability of having nicotine dependence in Americans of both European and African descent (Rice et al., 2012). A parallel study found that nonsense variants in CHRNA4 actually decreased the risk for nicotine dependence in Americans of both European and African descent (Haller et al., 2012). Moreover, these authors reported that an in vitro analysis revealed that the minor (protective) allele was associated with increased cellular response to nicotine. In male Japanese subjects, the CHRN2B polymorphism (rs4845652) may confer protection against nicotine dependence, whereas a combination of this polymorphism with the CHRNA4 risk polymorphism (rs1044397) leads to higher nicotine dependence scores (Chen et al., 2013).

Similar to the study in Japan (Chen et al., 2013), an early study with male Chinese smokers revealed that the CHRNA4 risk polymorphism (rs1044396) was significantly associated with age at smoking initiation and the CHRNA4 risk polymorphisms (rs1044396 and rs1044397) were associated with nicotine dependence (Chu et al., 2011). In subjects from the Center on Antisocial Behavior (CBIR) study found that the CHRNB3 risk polymorphism (rs1451240) significantly associated with nicotine dependence in Americans of both European and African descent (Rice et al., 2012). Combined, these findings indicate that multiple polymorphisms associated with nAChR gene have been identified that predict dependency to a number of abuse substances or associated behaviors across national, ethnic and psychiatric groups. The fact that these results span several populations supports the reliability of these findings.

**SUMMARY AND CONCLUSIONS**

Due to the limited efficacy of existing FDA approved medications as indicated by continued significant relapse rates, there is a great impetus for determining alternative neuronal brain targets and strategies in the treatment of addiction. As outlined above, significant progress has been made in determining the role that the nicotinic cholinergic system plays in alcohol and drug dependence through both preclinical and clinical studies. Therefore, modulation of brain nAChRs represents a potential therapeutic strategy for treating alcohol and drug dependence. In general, the variety of nAChR subtypes, the respective stoichiometry profile of their respective subunits, their specific localization within the brain, and downstream effects from nAChR activation have been shown to mediate, at least in part, the complex behavioral and neurobiological effects of alcohol and drugs of abuse. Recent studies support the clinical management of alcohol dependence with varenicline and other nAChR partial agonists and/or antagonists, such as mecamylamine, especially among heavy smokers. Further, both chronic alcohol drinking and chronic nicotine exposure affect neural circuits (e.g., hippocampus and prefrontal cortex) mediating cognitive activities such as attention and decision-making. Hence, the use of nAChR-based ligands could improve impaired cognitive function associated with chronic alcohol or nicotine exposure facilitating cognitive and behavioral treatments targeting addiction. Regarding reward and reinforcement, chronic alcohol and drug use enhances cholinergic activity within the mesocorticolimbic dopamine system (e.g., ventral tegmental area) that causes desensitization of nAChR-mediated activity. Therefore, the level and role of neuroplastic changes within this reward system requires further investigation. While the development of nAChR subtype-specific ligands holds great potential for future pharmacotherapies targeting alcohol and drug dependence, possible adverse side-effects associated with these ligands...
reiterates the need to study these effects before committing them to clinical use. Nevertheless, the substantial health burden that alcohol and drug addiction place on society mandates the recognition that clinical efficacy may outweigh the possible side-effects of a particular nicotinergic system modulator.

In addition, while a global role for the cholinergic system in addiction has been established, the unique role for specific nAChR subtypes has yet to be determined. As these issues are studied, the field will have a better understanding of the neurocircuitry as well as cellular and molecular processes involved in alcohol and drug dependence. With this knowledge, we will be able to develop small molecules that can disrupt, and possibly reverse, the addictive process associated with the cholinergic system’s, as well as its control of other neuromodulatory systems, mediation of alcohol and drug dependence. Despite some mixed results, or limited outcomes, of clinical or human laboratory trials using some of these nAChR ligands, there remains considerable potential for additional translational research on the cholinergic system in developing therapeutic management strategies for alcohol and drug dependence. The breadth of these findings in combination with a substantial literature on Genome Wide Association Studies, argue persuasively that future drug development will include small molecules targeting central cholinergic activity resulting in more effective treatments for alcohol, nicotine and other drug addictions.

ACKNOWLEDGMENTS

Preparation of this manuscript was supported in part by the grants from Juhne Endowment Fund and South Dakota State University Foundation (Shafiqur Rahman); AA13522 (Richard L. Bell), and AA020936 (Eric A. Engleman, Richard L. Bell) from the National Institutes of Health (NIH)/National Institute on Alcohol Abuse and Alcoholism (NIAAA). The views expressed herein are solely those of the authors and do not necessarily reflect the views of the funding organizations, NIH or NIAAA.

REFERENCES

Albuquerque, E. X., Pereira, E. F. R., Alkondon, M., and Rogers, S. W. (2009). Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol. Rev. 89, 73–120. doi:10.1152/physrev.00015.2008

Alkondon, M., Pereira, E. F., Barbosa, C. T., and Albuquerque, E. X. (1997). Neuronal nicotinic Acetylcholine receptor activation modulates γ-aminobutyric acid release from CA1 neurons of rat hippocampal slices. J. Pharmacol. Exp. Ther. 283, 1396–1411.

Anantharaman, D., Chabrier, A., Gaborieau, V., Franceschi, S., Herrero, R., Conlon, M. S., and Bewick, M. A. (2011). Single nucleotide polymorphisms as pharmacotherapeutic targets for the treatment of alcohol use disorders. CNS Neurol. Dis. Drug Targets 9, 60–76. doi:10.2174/187152710799656957

Bell, R. L., Eiler, B. J., Cook, J. B., and Rahman, S. (2009). Nicotinic receptor ligands reduce ethanol intake by high alcohol-drinking HAD-2 rats. Alcohol 43, 581–592. doi:10.1016/j.alcohol.2009.09.027

Bell, R. L., Sable, H. J. K., Colombo, G., Hyytia, P., Rodd, Z. A., and Lumeng, L. (2012). Animal models for medications development targeting alcohol abuse using selectively bred rat lines: neurobiological and pharmacological validity. Pharmaco. Biochem. Behav. 103, 119–155. doi:10.1016/j.pbb.2012.07.007

Benowitz, N. L. (2009). Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu. Rev. Pharmacol. Toxicol. 49, 57–71. doi:10.1146/annurev.pharmtox.48

Biala, G., and Staniek, N. (2010). Varenicline and mecamylamine attenuate locomotor sensitization and cross-sensitization induced by nicotine and morphine in mice. Pharmacol. Biochem. Behav. 96, 141–147. doi:10.1016/j.pbb.2010.04.022

Bito-Onon, J. J., Simms, J. A., Chatterjee, S., Holgate, J., and Bartlett, S. E. (2011). Varenicline, a partial agonist at neuronal nicotinic acetylcholine receptors, reduces nicotine-induced increases in 20% ethanol operant self-administration in Sprague-Dawley rats. Addict. Biol. 16, 440–449. doi:10.1111/j.1369-1600.2010.00309.x

Blomqvist, O., Engell, A. J., Nisbrandt, H., and Söderpalm, B. (1993). The mesolimbic dopamine-activating properties of ethanol are antagonized by mecamylamine. Eur. J. Pharmacol. 249, 207–213. doi:10.1016/0014-2999(93)90343-J

Blomqvist, O., Ericson, M., Johnson, D. H., Engell, A. J., and Söderpalm, B. (1996). Voluntary ethanol intake in the rat: effects of nicotinic acetylcholine receptor blockade or subchronic nicotine treatment. Eur. J. Pharmacol. 314, 257–267. doi:10.1016/S0014-2999(96)00838-3

Blomqvist, O., Hernández-Avilía, C. A., Van Kirk, J., Rose, J. E., and Kranzler, H. R. (2002). Mecamylamine modifies the pharmacokinetics and reinforcing effects of alcohol. Alcohol Clin. Exp. Res. 26, 326–331. doi:10.1111/j.1530-0272.2002.tb02541.x

Brons, U., Wedenoja, I., Largeo, M. R., Korhonen, T., Pitkianemi, J., Keski-Koivu, M., and Alkondon, M., Pereira, E. F., Barbosa, C. T., and Albuquerque, E. X. (2009). Combined effects of alcohol and drug dependence. Alcoholism: Clin. Exp. Res. 32, 364–370. doi:10.1111/j.1530-0272.2008.00932.x

Buccafusco, J. J., Beach, W., and Terry, A. V. (2009). Desensitization of nicotinic acetylcholine receptors as a strategy for drug development. J. Pharmacol. Exp. Ther. 328, 364–370. doi:10.1124/jpet.108.145292

Champtiaux, N., Gotti, C., Cordero-Erausquin, M., David, D. J., Przybylski, C., Lena, C., et al. (2003). Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knock-out mice. J. Neurosci. 23, 7820–7829. Available online at: http://www.jneurosci.org/content/23/21/7820.long

Champtiaux, N., Han, Z. Y., Bessis, A., Rossi, F. M., Zoli, M., Marubbio, L., et al. (2002). Distribution and pharmacology of alpha 6-containing nicotinic acetylcholine receptors analyzed with mutant mice. J. Neurosci. 22, 1208–1217. Available online at: http://www.jneurosci.org/content/22/4/1208.long

Champtiaux, N., Kalivas, P. W., and Bardo, M. T. (2006). Contribution of dihydro-beta-erythroidine sensitive nicotinic acetylcholine receptors in the ventral tegmental area to cocaine-induced behavioral sensitization in rats. Behav. Brain Res. 168, 120–126. doi:10.1016/j.bbr.2005.10.017

Changuej, P. J. (2010). Nicotine addiction and nicotinic receptors: lessons from genetically modified mice. Nat. Rev. Neurosci. 11, 389–401. doi:10.1038/nrn2849

Chatterjee, S., and Bartlett, S. E. (2010). Neuronal nicotinic acetylcholine receptors as pharmacotherapeutic targets for the treatment of alcohol use disorders. CNS Neurol. Dis. Drug Targets 9, 60–76. doi:10.2174/187152710799656957

Chen, H. I., Shinkai, T., Utsunomiya, K., Yamada, K., Sakata, S., Fukunaka, Y., et al. (2013). Possible association of nicotinic acetylcholine receptor gene (CHRNA4 and CHRN2) polymorphisms with nicotine dependence in Japanese males: an exploratory study. Pharmacopsychopharmacology 36, 603–615. doi:10.1016/j.npp.2010.191

Chi, H., and de Wit, H. (2003). Mecamylamine attenuates the subjective stimulant-like effects of alcohol in social drinkers. Alcohol Clin. Exp. Res. 27, 780–786. doi:10.1098/ALC.0000065435.126086.24

Chu, C. I., Yang, Y. C., Wei, I. X., and Zhang, L. (2011). Associations of nicotinic acetylcholine receptor subunit α4-4 polymorphisms with smoking behaviors in Chinese male smokers. Chin. Med. J. 124, 1634–1638.

Clark, L., and Robbins, T. (2002). Decision-making deficits in drug addiction. Trends Cogn. Sci. 6, 361. doi:10.1016/S1364-6613(02)01960-5

Clarke, P., and Reuben, M. (1996). Release of [3H]—noradrenaline from rat hippocampal Synaptosomes by nicotine: mediation by different nicotinic receptor subtypes from striatal [3H]—dopamine release. Br. J. Pharmacol. 117, 599–606. doi:10.1111/j.1476-5381.1996.tb1322x

Coe, J. W., Brooks, P. R., Vetrino, M. G., Wirtz, C. M., Arnold, E. P., Huang, J., et al. (2005). Varenicline: an α4β2β2 nicotinic receptor partial agonist for smoking cessation. J. Med. Chem. 48, 3474–3477. doi:10.1021/jm050069n

Conlon, M. S., and Bewick, M. A. (2011). Single nucleotide polymorphisms in CHRNA5 rs16969698, CHRNA3 rs578776, and LOC123688 rs8034191 are
associated with heaviness of smoking in women in northeastern Ontario, Canada. *Nic. Tob. Res.* 13, 1076–1083. doi: 10.1093/ptr/ntr140

Corrigall, W. A., Franklin, K. B. J., Coen, K. M., and Clarke, P. B. S. (1992). The mesolimbic dopamine system is implicated in the reinforcing effects of nicotine. *Psychopharmacology* 107, 285–289. doi: 10.1007/BF02251419

Crooks, P. A., Bardo, M. T., and Dwoskin, L. P. (2014). Nicotinic receptor antagonists as treatments for nicotine abuse. *Adv. Pharmacol.* 69, 513–551. doi: 10.1006/rfph.1997.0878-0-12-420118-7.00013-5

Damaj, M. I., Patrick, G. S., Creasy, K. R., and Martin, B. R. (1997). Pharmacology of lobeline, a nicotinic receptor ligand. *J. Pharmacol. Exp. Ther.* 282, 410–419.

Dani, J. A., and Bertrand, D. (2007). Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. *Annu. Rev. Pharmacol. Toxicol.* 47, 699–729. doi: 10.1146/annurev.pharmtox.47.120505.105214

Davies, D. L., Bortolato, M., Finn, D. A., Ramaker, M. J., Barak, S., Ron, D., et al. (2013). Recent advances in the discovery and preclinical testing of novel compounds for the prevention and/or treatment of alcohol use disorders. *Alcohol. Clin. Exp. Res.* 37, 8–15. doi: 10.1111/j.1530-0277.2012.01846.x

De La Garza, R. II, Newton, T. F., Haile, C. N., Yoon, J. H., Nerumalla, C. S., Mahoney, J. I. III, et al. (2012). Rivastigmine reduces "likely to use methamphetamine" in methamphetamine-dependent volunteers. *Prog. Neuropsychopharmacol. Biol. Psychiatry* 37, 8–15. doi: 10.1111/j.1530-0277.2012.01846.x

De La Garza, R., and Yoon, J. H. (2011). Evaluation of the effects of rivastigmine on cigarette smoking by methamphetamine-dependent volunteers. *Prog. Neuropsychopharmacol. Biol. Psychiatry* 35, 1827–1830. doi: 10.1016/j.pnpbp.2011.07.006

Diehl, A., Nakovics, H., Mutschler, J., Hermann, D., and Kiefer, F. (2009). Rivastigmine reduces tobacco craving in alcohol-dependent smokers. *Pharmacopsychiatry* 42, 89–94. doi: 10.1505/0028-1102925

Dwoskin, L. P., Smith, A. M., Wooters, T. E., Zhang, Z., Crooks, P. A., and Bardo, M. T. (2009). Nicotinic receptor-based therapeutics and candidates for smoking cessation. *Biochem. Pharmacol.* 78, 732–743. doi: 10.1016/j.bcp.2009.06.002

Ericson, M., Blomqvist, O., Engbl A., and Söderpalm, B. (1998). Voluntary dowskin, L. P., Smith, A. M., Wooters, T. E., Zhang, Z., Crooks, P. A., and Söderpalm, B. (2007). Nicotinic acetylcholine receptor antagonists for nicotine withdrawal: evidence from genetically modified mice. *Behav. Brain Res.* 194, 53–61. doi: 10.1016/j.bbr.2007.05.023

Haller, G., Druley, T., Vallania, E. F., Mitra, R. D., Pabreza, L. A., Wolfe, B. B., and Kellar, K. (1992). A heterogeneity and complexity of native brain nicotinic receptors. *Biochem. Pharmacol.* 41, 1102–1111. doi: 10.1016/0006-2952(92)90759-H

Guillem, K., and Peoples, L. L. (2010). Varenicline effects on cocaine self-administration and reinstatement behavior. *Behav. Pharmacol.* 21, 96–103. doi: 10.1097/FBP.0b013e328336ec96

Haller, G., Druley, T., Vallania, E. F., Mitra, R. D., Li, P., Akk, G., et al. (2012). Rare missense variants in CHRNB4 are associated with reduced risk of nicotine dependence. *Hum. Mol. Genet.* 21, 647–655. doi: 10.1093/hmg/ddr498

Hansen, S. T., and Mark, G. P. (2007). The nicotinic acetylcholine receptor antagonist mecamylamine prevents escalation of cocaine self-administration in rats with extended daily access. *Psychopharmacology* 194, 53–61. doi: 10.1007/s00213-007-0822-z

Hart, N., Roach, A., Miller, D. K., and Nation, J. R. (2010). Dose-dependent attenuation of heroin self-administration with lobeline. *J. Pharmacpsychopharmacol.* 24, 51–55. doi: 10.1026/00981109082119

Harvey, A. L. (1995). The pharmacology of galantamine and its analogues. *Pharmacol. Ther.* 68, 113–128. doi: 10.1016/0163-7256(95)02002-0

Hauser, S. R., Getachew, B., Oster, S. M., Dhaker, R., Ding, Z.-M., Bell, R. L., et al. (2012). Nicotine modulates alcohol-seeking and relapse by alcohol-prefering (P) rats in a time dependent manner. *Alcohol. Clin. Exp. Res.* 36, 43–54. doi: 10.1111/j.1530-0277.2011.01579.x

Hendrickson, L. M., Guilford, M. J., and Tapper, A. R. (2013). Neuronal nicotinic acetylcholine receptors: common molecular substrates of nicotine and alcohol dependence. *Front. Psychiatry* 4:29. doi: 10.3389/fpsyt.2013.00029

Hendrickson, L. M., Zhao-Sha, R., Pang, X., Gardner, P. D., and Tapper, A. R. (2010). Activation of alpha4* nAChRs is necessary and sufficient for varenicline-induced reduction of alcohol consumption. *J. Neurosci.* 30, 10169–10176. doi: 10.1523/JNEUROSCI.2601-10.2010

Hendrickson, L. M., Zhao-Sha, R., and Tapper, A. R. (2009). Modulation of ethanol drinking-in-the-dark by mecamylamine and nicotinic acetylcholine receptor agonists in C57BL/6J mice. *Psychopharmacology* 204, 563–572. doi: 10.1007/s00213-009-1488-5

Hoff, N. R., Corley, R. P., McQueen, M. B., Huizinga, D., Menard, S., and Ehringer, M. A. (2009). SNPs in CHRNA6 and CHRNA8 are associated with alcohol consumption in a nationally representative sample. *Genes Brain Behav.* 8, 631–637. doi: 10.1111/j.1601-183X.2009.00495.x

Hogg, R. C., Raggenbass, M., and Bertrand, D. (2003). Nicotinic acetylcholine receptors from structure to brain function. *Biochem. Pharmacol.* 147, 1–46. doi: 10.1016/j.bcp.2012.04.014

Hurst, R., Rollema, H., and Bertrand, D. (2013). Nicotinic acetylcholine receptors from basic science to therapeutics. *Pharmacol. Ther.* 137, 22–54. doi: 10.1016/j.pharmthera.2012.08.012

Janes, A. C., Smoller, J. W., David, S. P., Frederick, B. D., Haddad, S., Basu, A., et al. (2012). Association between CHRNA5 genetic variation at rs1696968 and brain reactivity to smoking images in nicotine dependent women. *Drug Alcohol Depend.* 120, 7–13. doi: 10.1016/j.drugalcdep.2011.04.009

Kamens, H. M., Anderson, J., and Picciotto, M. R. (2010). Galantamine, an acetylcholinesterase inhibitor and positive allosteric modulator of nicotinic acetylcholine receptors attenuates nicotine taking and seeking in rats. *Neuropsychopharmacology* 37, 2310–2321. doi: 10.1038/npp.2012.83

Kamens, H. M., Orley, R. P., McQueen, M. B., Stallings, M. C., Hopfer, C. J., Crowley, T. I., et al. (2013). Nominal association with CHRNA4 variants and nicotine dependence. *Genes Brain Behav.* 12, 297–304. doi: 10.1111/gbb.12021
Litten, R. Z., Egli, M., Heilig, M., Cui, C., Fertig, J. B., Ryan, M. L., et al. (2012). Nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei. J. Neurosci. 21, 1452–1463.

Koob, G. F., and Volkow, N. D. (2010). Neurocircuitry of addiction. Annu. Rev. Psychol. 61, 25–54. doi: 10.1146/annurev.psych.103108.955501

Keskitalo-Vuokko, K., Pitkaniemi, J., Broms, U., Heliovaara, M., Aromaa, A., Jarvela, I., et al. (2012). Effect of a novel nicotinic receptor antagonist, N,N-dimethyl nicotinamide, on drinking behavior. Alcohol. Clin. Exp. Res. 36, 1066–1072. doi: 10.1111/j.1530-0277.2012.01302.x

Koob, G. F., and Volkow, N. D. (2009). Neurobiological and clinical aspects of nicotine dependence. Annu. Rev. Med. 60, 135–151. doi: 10.1146/annurev.med.60.102807.185704

Koob, G. F., and Volkow, N. D. (2002). Neurobiological and clinical aspects of nicotine dependence. Annu. Rev. Med. 53, 419–440. doi: 10.1146/annurev.med.53.090601.140541
Paterson, D., and Nordberg, A. (2000). Neuronal nicotinic receptors in the human brain. Prog. Neurobiol. 61, 75–111. doi: 10.1016/S0301-0082(99)00045-3

Perry, D. C., Xiao, Y., Nguyen, H. N., Musachio, J. L., Dávila–García, M. I., and Kellar, K. J. (2002). Measuring nicotinic receptors with characteristics of α4β2 and α3β4 subtypes in rat tissues by autoradiography. J. Neurochem. 82, 468–481. doi: 10.1046/j.1471-4159.2002.00951.x

Picciotto, M. R., Zoli, M., Lena, C., Bessis, A., Lallemand, Y., Le Novere, N., et al. (1995). Abnormal avoidance learning in mice lacking functional high-affinity nicotine receptor in the brain. Nature 374, 65–67. doi: 10.1038/374065a

Picciotto, M. R., Zoli, M., Rimondini, R., Lena, C., Marubio, L. M., Pich, E. M., et al. (1998). Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature 391, 173–177. doi: 10.1038/43413

Plebani, J. G., Lynch, K. G., Yu, Q., Pettinani, H. M., O’Brien, C. P., and Kampman, K. M. (2012). Results of an initial clinical trial of varenicline for the treatment of cocaine dependence. Drug Alcohol Depend. 121, 163–166. doi: 10.1016/j.drugalcdep.2011.08.025

Quick, M. W., and Lester, R. A. J. (2002). Desensitization of neuronal nicotinic receptors. J. Neurobiol. 53, 457–478. doi: 10.1002/neu.10109

Rahman, S. (2013). Nicotinic receptors as therapeutic targets for drug addiction. CNS Neurol. Dis. Drug Targets 12, 633–640. doi: 10.2174/1871527311312050011

Rahman, S., Neugebauer, N. M., Zhang, Z., Crooks, P. A., Dwoskin, L. P., and Bardo, M. T. (2007). The effects of novel N,N-dodecane-1,12-diyl-bis-3-picolinil dibromide on acute and repeated nicotine-induced increases in extracellular dopamine responses in rat nucleus accumbens. Neuropsychopharmacology 32, 755–763. doi: 10.1016/j.neuropsychopharmacology.2006.09.012

Rahman, S., and Prendergast, M. A. (2012). Brain cholinergic receptor system as a target for treating alcohol dependence. Recent Pat. CNS Drug Discov. 7, 145–150. doi: 10.2174/1574891912800673173

Reus, V. I., Obach, R. S., Roe, J. W., Faesel, H., Rollemma, H., Watsky, E., et al. (2007). Varenicline: new treatment with efficacy in smoking cessation. Drugs Today 43, 65–75. doi: 10.1358/dot.2007.43.2.1069956

Rezvani, A. H., Cauley, M., Xiao, Y., Kellar, K. J., and Levin, E. D. (2013). Effects of chronic sazetidine-A, a selective α4β2 neuronal nicotinic acetylcholine receptors desensitizing agent on pharmacologically-induced impaired attention in rats. Psychopharmacology 226, 35–43. doi: 10.1007/s00213-012-2895-6

Rezvani, A. H., Slade, S., Wells, C., Petro, A., Lumeng, L., Li, T.-K., and et al. (2010). Effects of sazetidine-A a selective alpha(2)beta2 nicotinic acetylcholine receptor desensitizing agent on alcohol and nicotine self-administration in selectively bred alcohol-prefering (P) rats. Psychopharmacology 211, 161–174. doi: 10.1007/s00213-010-1789-8

Ross, S. A., Wong, J. Y. Clifford, J. I., Kimellin, A., Massalas, J. S., Horne, M. K., et al. (2000). Phenotypic characterization of an alpha 4 neuronal nicotinic acetylcholine receptor subunit knock-out mouse. J. Neurosci. 20, 6431–6441.

Sajja, R. K., Dwivedi, C., and Rahman, S. (2010). Nicotinic ligands modulate ethanol-induced Dopamine functions in mice. Pharmacology 86, 168–173. doi: 10.1159/000317063
acetylcholine receptor antagonist blocks nicotine self-administration in rats. *Neuropsychopharmacology* 37, 1367–1376. doi: 10.1038/npp.2011.322

Tuesta, L. M., Fowler, C. D., and Kenny, P. J. (2011). Recent advances in understanding nicotinic receptor signaling mechanisms that regulate drug-self administration behavior. *Biochem. Pharmacol.* 82, 984–995. doi: 10.1016/j.bcp.2011.06.026

Tutka, P., and Zatoński, W. (2006). Cytisine for the treatment of nicotine addiction: from a molecule To therapeutic efficacy. *Pharmacol. Rep.* 53, 777–798.

Uhl, G. R., Drgonova, J., and Hall, F. S. (2014). Curious cases: altered dose-response relationships in addiction genetics. *Pharmacol. Ther.* 141, 335–346. doi: 10.1016/j.phamacolther.2013.10.013

Verrico, C. D., Mahoney, J. J. III, Thompson-Lake, D. G., Bennett, R. S., Newton, T. F., De La Garza, R., et al. (2014). Safety and efficacy of varenclline to reduce positive subjective effects produced by methamphetamine in methamphetamine-dependent volunteers. *Int. J. Neuropsychopharmacol.* 17, 223–233. doi: 10.1017/S146114571300134X

Volkow, N. D., and Baler, R. D. (2014). Addiction science: Uncovering neurobiological complexity. *Neuropsychopharmacology* 76( Pt B), 235–249. doi: 10.1016/j.neuropharm.2013.05.007

Volkow, N. D., and Skolnick, P. (2012). New medications for substance use disorders: challenges and opportunities. *Neuropsychopharmacology* 37, 290–292. doi: 10.1038/npp.2011.84

Wang, S. D., van der Vaart, A., Xu, Q., Senevirante, C., van der Vaart, A., Xu, Q., Senevirante, C., Pomerleau, O. F., Payne, T. J., Wooltorton, J. R., Pidoplichko, V. I., Broide, R. S., and Dani, J. A. (2003). Nicotinic Receptors modulating dopamine release in the rat striatum. *J. Neurosci.* 23, 429–431. Available online at: http://www.jneurosci.org/content/23/9/3332

Wilkie, G. I., Hutson, P. H., Stephens, M. W., Whiting, P., and Wonnacott, S. (1993). Hippocampal Nicotinic autoreceptors modulate acetylcholine release. *Biochem. Soc. Trans.* 21, 429–431.

Wise, R. A., and Koob, G. F. (2014). The development and maintenance of alcohol addiction. *Neuropsychopharmacology* 39, 254–262. doi: 10.1038/npp.2013.261

Wojas-Krawczyk, K., Krawczyk, P., Biernacka, B., Grzybek, M., Kolodziej, P., Kucharczyk, T., et al. (2012). The polymorphism of the CHRNA5 gene and the strength of nicotine addiction in lung cancer and COPD patients. *Eur. J. Cancer Prev.* 21, 111–117. doi: 10.1097/EJC.0b013e328354c9d0

Wonnacott, S., Kaiser, S., Mogg, A., Soliakov, L., and Jones, I. W. (2000). Presynaptic nicotinic Receptors inating dopamine release in the rat striatum. *Eur. J. Pharmacol.* 393, 51–58. doi: 10.1016/S0041-2990(99)00005-4

Wooltorton, J. R., Pidoplichko, V. I., Broide, R. S., and Dani, J. A. (2003). Differential desensitization and distribution of nicotinic acetylcholine receptor subtypes in midbrain dopamine areas. *J Neurosci.* 23, 3176–3185. Available online at: http://www.jneurosci.org/content/23/8/3176

Wouda, J. A., Riga, D., De Vries, W., Stegeman, M., van Mourik, Y., Schetters, D., et al. (2011). Varenicline attenuates cue-induced relapse to alcohol but not nicotine seeking while reducing inhibitory response control. *Psychopharmacology* 216, 267–277. doi: 10.1007/s00213-011-2213-8

Xiao, Y., Fan, H., Musachio, J. L., Wei, Z. L., Chellappan, S. K., Kozikowski, A. P., et al. (2006). Saizetidine-A, a novel ligand that desensitizes α4β2 nicotinic acetylcholine receptors without activating them. *Mol. Pharmacol.* 70, 1454–1460. doi: 10.1124/mol.106.027318

Yang, X., Criswell, H. E., and Breese, G. R. (1996). Nicotine-induced inhibition in medial septum Involves activation of presynaptic nicotinic cholinergic receptors on gamma-aminobutyric acid-Containing neurons. *J. Pharmacol. Exp. Ther.* 276, 482–489.

Young, E. M., Mahler, S., Chi, H., and de Wit, H. (2005). Mecamylamine and ethanol preference in healthy volunteers. *Alcohol Clin. Exp. Res.* 29, 58–65. doi: 10.1097/01.ALC.0000150007.34702.16

Zachariou, V., Caldarone, B. J., Weathers-Lowin, A., George, T. P., Elsworth, J. D., Roth, R. H., et al. (2001). Nicotine receptor inactivation decreases sensitivity to cocaine. *Neuropsychopharmacology* 24, 576–589. doi: 10.1016/S0893-133X(00)00224-4

Zanetti, L., de Kerchove D’Exaerde, A., Zanardi, A., Changeux, J. P., Picciotto, M. R., and Zoli, M. (2006). Inhibition of both alpha7* and beta2* nicotinic acetylcholine receptors is necessary to prevent development of sensitization to cocaine-elicted increases in extracellular dopamine levels in the ventral striatum. *Psychopharmacology* 187, 181–188. doi: 10.1007/s00213-006-0419-y

Zhu, A. Z., Renner, C. C., Hatusuka, D. K., Benowitz, N. L., and Tyndale, R. F. (2013). CHRNA5-A3-B4 genetic variants alter nicotine intake and interact with tobacco use to influence body weight in Alaska Native tobacco users. *Addiction* 108, 1818–1828. doi: 10.1111/add.12250

Zoli, M., Léna, C., Picciotto, M. R., and Changeux, J. P. (1998). Identification of four classes of brain nicotinic receptors using beta2 mutant mice. *J. Neurosci.* 18, 4461–4472.

Zoli, M., Moretti, M., Zanardi, A., McIntosh, J. M., Clementi, F., and Gotti, C. (2002). Identification of the nicotinic receptor subtypes expressed on dopaminergic terminals in the rat striatum. *J. Neurosci.* 22, 8785–8789. Available online at: http://www.jneurosci.org/content/22/20/8785

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.